A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors With Expansion to Selected Indications in Asia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs MSB 0011359C (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck KGaA
- 13 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 25 May 2017 Planned number of patients changed from 111 to 117.
- 25 Jan 2017 Planned End Date changed from 1 Aug 2019 to 1 Mar 2019.